These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34809430)

  • 1. Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
    Fu W; Zhang M; Liao J; Tang Q; Lei Y; Gong Z; Shan L; Duan M; Chai X; Pang J; Tang C; Wang X; Xu X; Li D; Sheng R; Hou T
    J Med Chem; 2021 Dec; 64(23):17221-17238. PubMed ID: 34809430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
    Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
    Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
    Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
    Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational dynamics of androgen receptors bound to agonists and antagonists.
    Gim HJ; Park J; Jung ME; Houk KN
    Sci Rep; 2021 Aug; 11(1):15887. PubMed ID: 34354111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
    Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
    J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
    Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity.
    Tamura H; Yoshioka M; Hasegawa M; Hosoda A; Matsugi M; Akamatsu M
    Bioorg Med Chem; 2013 Jun; 21(11):2968-74. PubMed ID: 23611768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation.
    Chen H; Zhou Y; Wang X; Chai X; Wang Z; Wang E; Xu L; Hou T; Li D; Duan M
    Adv Sci (Weinh); 2024 May; 11(19):e2309261. PubMed ID: 38481034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico and in vitro assessment of androgen receptor antagonists.
    Serçinoğlu O; Bereketoglu C; Olsson PE; Pradhan A
    Comput Biol Chem; 2021 Jun; 92():107490. PubMed ID: 33932781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator.
    Liu N; Zhou W; Guo Y; Wang J; Fu W; Sun H; Li D; Duan M; Hou T
    J Chem Inf Model; 2018 Aug; 58(8):1652-1661. PubMed ID: 29993249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
    Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction.
    Wahl J; Smieško M
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
    Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.